Saudi Arabia Surgical Sutures Market Size, Share & Forecast, By Product Type, Material Type & End User, 2026–2031

The Saudi Arabia Surgical Sutures Market was worth USD 98.6 million in 2025. The estimate represents supplier revenue from sterile surgical sutures and associated wound-closure products sold for domestic use across public hospitals, private hospitals, ambulatory centers and specialty clinics. It excludes surgical staples, skin adhesives, non-sterile threads and internal hospital transfer costs. The value was triangulated from company revenues, customs flows, procedure volumes, unit consumption and channel pricing. Approximately 18.6 million sterile units were consumed at a blended average selling price of USD 5.30 per unit.

The market is projected to reach USD 151.6 million by 2031, representing a CAGR of 7.43% from the 2025 base. Annual growth is expected to accelerate as surgical capacity, insurance coverage and private provider throughput expand. Volume is forecast to rise to 26.8 million units, while the blended selling price reaches USD 5.66 through greater use of synthetic absorbable, antibacterial and barbed products. The forecast assumes continued hospital investment, stable regulatory access and gradual localization without severe tender-price disruption or prolonged supply constraints.

Profit pools will shift toward synthetic absorbable, antibacterial, barbed and procedure-specific products rather than undifferentiated conventional threads. These categories can command higher prices when they improve handling, reduce closure time or support infection-prevention objectives. Average market value per unit is projected to increase from USD 5.30 in 2025 to USD 5.66 in 2031 even as centralized tenders continue to constrain commodity pricing. Additional margin opportunities will emerge in surgeon education, specialty inventory management, procedure packs and direct private-hospital contracting.

Import dependence is the principal structural risk because approximately 91% of 2025 demand is supplied through imported products. Saudi Arabia imported USD 85.8 million of HS 300610 products in 2024, while exports were only USD 4.6 million. Dependence on external manufacturing creates exposure to freight disruption, supplier allocation, regulatory renewal delays and extended replenishment cycles. The risk is amplified by SKU complexity because hospitals often require precise combinations of filament, gauge, length, needle curvature and absorption performance that cannot be substituted immediately.

Saudi Arabia ranks first by modeled 2025 surgical-suture market value among the selected peer countries of the UAE, Turkey, Kuwait and Egypt. Its USD 98.6 million market exceeds the UAE's USD 74.8 million and Turkey's USD 69.8 million. Saudi Arabia also recorded the peer group's largest reported HS 300610 import value at USD 85.8 million in 2024. Its forecast CAGR of 7.43% is above Turkey's 6.80% and Kuwait's 5.90%, reflecting stronger healthcare investment, insured utilization and centralized procurement scale.

Surgical procedure volume has the greatest direct effect because every qualifying procedure generates demand for specific suture materials, gauges, needles and closure techniques. Saudi hospitals reported approximately 1.87 million surgical interventions in 2023, including 849,884 procedures in private facilities. Insurance growth reinforces this demand by expanding access to scheduled procedures, with 14.46 million beneficiaries reported in 2024 and a projected 22 million by 2030. The combined effect supports both high-volume tender products and premium sutures used in complex procedures.

A new supplier should enter through a licensed Saudi distributor with proven SFDA registration, NUPCO tender and hospital conversion capabilities. The initial portfolio should cover high-volume synthetic absorbable and non-absorbable products before expanding into antibacterial, barbed or automated systems. Commercial readiness requires local inventory, surgeon evaluation, product traceability and tender documentation. With approximately 38 active manufacturers and suppliers, price alone is unlikely to create durable share. Local packaging or sterilization can improve lead times and strengthen alignment with public-sector localization objectives.